Device Thrombogenicity Emulation: An *In Silico* Predictor of *In Vitro* and *In Vivo* Ventricular Assist Device Thrombogenicity

Wei Che Chiu1, Phat L. Tran2, Zain Khalpey2, Eric Lee3, Yi-Ren Woo3, Marvin J. Slepian2 & Danny Bluestein1

Ventricular assist devices (VAD), a mainstay of therapy for advanced and end-stage heart failure, remain plagued by device thrombogenicity. Combining advanced *in silico* and *in vitro* methods, Device Thrombogenicity Emulation (DTE) is a device design approach for enhancing VAD thromboresistance. Here we tested DTE efficacy in experimental VAD designs. DTE incorporates iterative design modifications with advanced CFD to compute the propensity of large populations of platelets to activate by flow-induced stresses (statistically representing the VAD 'Thrombogenic Footprint').

The DTE approach was applied to a VAD (MINdTE) design with a favorable thromboresistance profile and compared against a design (MAXdTE) that generated an intentionally poor thromboresistance profile. DTE predictions were confirmed by testing physical prototypes *in vitro* by measuring VAD thrombogenicity using the modified prothrombinase assay. Chronic *in vivo* studies in VAD implanted calves, revealed MINdTE calf surviving well with low platelet activation, whereas the MAXdTE animal sustained thromboembolic strokes. DTE predictions were confirmed, correlating with *in vitro* and *in vivo* thrombogenicity, supporting utility in guiding device development, potentially reducing the need for animal studies.

With a steadily increasing clinical burden of heart failure (HF), coupled with a persistent heart transplant donor organ shortage worldwide, ventricular assist devices (VADs) have become the standard of care for advanced and end-stage HF patients. In recent years several VADs have been granted regulatory approval for bridge-to-transplant (BTT) and/or destination therapy (DT) indications by the Food and Drug Administration (FDA)1,2,3. All current approved VAD designs generate non-physiological blood flow patterns, imparting supra-physiologic shear stress to circulating platelets, ultimately activating the blood hemostatic response4. As a result, device recipients are prone to post-implant thromboembolic complications, mandating lifelong antithrombotic regimens5,6. The management of these pharmacologic-al regimens remains a major clinical challenge. Thrombotic complications are routinely reported in these FDA approved device recipients 7–14. Unfortunately current antithrombotic therapy, recently demonstrated to have limited overall efficacy15,16, may in fact lead to secondary severe complications, e.g., excessive bleeding events17–20. Device design optimization for reducing shear-induced blood damage, and for avoidance of excessive anti-thrombotic therapy, is essential for fundamentally improving device thromboresistance and overall clinical safety and efficacy.

A device thromboresistance optimization methodology, Device Thrombogenicity Emulation (DTE), was introduced by our group21–23. The DTE combines *in silico* numerical simulations with *in vitro* measurements by correlating device hemodynamics with platelet activity coagulation markers – before and after iterative design modifications aimed at achieving optimized thromboresistance performance. Its efficacy was previously demonstrated in prosthetic heart valves and VADs studies21–25. In the MicroMed HeartAssist 5 VAD for example, following its thromboresistance optimization by DTE close to a one order of magnitude reduction in platelet activity was achieved (as compared to the predecessor design on which it was based- the DeBakey30 VAD)23. It additionally reduced platelet activity to a level that was far lower than that of a gold standard VAD – the Thoratec
HeartMate II (HMII)\textsuperscript{24} (the first VAD approved by the FDA for destination therapy). The DTE optimization process also achieved platelet activity reduction that was far more effective than conventional antiplatelet drugs regimen therapy, e.g., ASA and Dipyridamole which are routinely prescribed to device recipients\textsuperscript{16,26}. This \textit{in silico/in vitro} methodology can potentially reduce the research and development (R&D) costs by developing Mechanical Circulatory Support (MCS) devices that are optimized for thromboresistance before proceeding to costly \textit{in vivo} animal experiments, and prior to the FDA device approval regulatory process.

We tested the hypothesis that predictions of device thrombogenicity derived via the \textit{in silico} DTE methodology would correlate with both \textit{in vitro} and \textit{in vivo} evidence of actual platelet activation and thrombosis (Fig. 1). Here a single design prototype VAD (VAD\textsubscript{proto}) was provided by Abbott Labs with which the authors subsequently conducted an \textit{in silico} DTE baseline analysis. This \textit{in silico} analysis demonstrated minimal platelet activation and represented an “optimized” baseline design (MIN\textsubscript{DTE}; Fig. 2B). A modification to this baseline design was simulated and fabricated to yield maximal platelet activation (MAX\textsubscript{DTE}; Fig. 2B, inset). Both prototypes underwent extensive \textit{in vitro} comparative testing and chronic animal \textit{in vivo} studies to evaluate and validate the differential device thrombogenicity levels predicted by the DTE methodology following the design modifications.

Materials and Methods

\textit{In silico simulations}. A prototype VAD (VAD\textsubscript{proto}) was provided by Abbott Labs (Thoratec Corp., Pleasanton, CA – now Abbott Labs). VAD\textsubscript{proto} is an axial pump, which adapts several pump design concepts from its successful predecessor – HMII (Fig. 2A). VAD\textsubscript{proto} consists of a three-fin inlet stator (Fig. 2B, purple section) followed by a three blades impeller (Fig. 2B, pink section). An aft portion redirects flow outwardly 90° from the axis of the impeller (Fig. 2B, blue section). Hence, blood flow is redirected without the need for inflow and outflow elbow cannulae (Fig. 2B). Unlike the HMII VAD, and similar to current centrifugal type VAD designs, VAD\textsubscript{proto} is proposed to be inserted directly into the apex of the left ventricle and is smaller and lighter than the HMII (Fig. 2A). In order to confirm the DTE approach, a VAD\textsubscript{proto} pump was intentionally modified (5 mm segment of the impeller blade was removed; Fig. 2B, inset) with the intent to create a lower efficiency, high thrombogenicity pump (MAX\textsubscript{DTE}) to be used as a negative control. The comparative thrombogenic performance of the two variants was used to evaluate the efficacy of the DTE methodology.

ANSYS DesignModeler (ANSYS Inc., Lebanon, NH) was employed for geometry reconstruction in preparation for numerical mesh generation composed of solid and fluid domains that is needed for fluid structure interaction (FSI) simulations (Fig. 2B). The fluid domain of each pump was segmented into two sections – stator and rotor. For rotating mesh preparation, the fluid domain was divided into two symmetric sections according to the cylindrical symmetricity of the shroud\textsuperscript{27}. Straight cylindrical sections with the lengths of five-times hydraulic diameters were added at the inlet and the outlet to allow for the flow to become fully developed (Fig. 2B, green and turquoise blue sections for inlet and outlet, accordingly). Interfaces were defined between these sections. ANSYS Meshing (ANSYS Inc., Lebanon, NH) was utilized for preparing tetrahedral volumetric meshes of the models. Similar mesh algorithms were applied to ensure comparable mesh densities across the devices. Extra attention was paid to interface meshing to ensure matched mesh densities across the interfaces. Rigorous mesh independence studies were conducted and were achieved with mesh densities of approx. 17 million cells for both models.

ANSYS Fluent CFD solver (ANSYS Fluent Inc., Lebanon, NH) was utilized for conducting the FSI simulations. Blood was modeled as a two-phase Newtonian fluid with viscosity and density of 0.0035 kg/m-s and 1,080 kg/m$^3$. The SST $k$-$\omega$ turbulent model was utilized for both studies due to its superior performance for simulating transient turbulent flows and its ability to accurately predict pressure head in VAD simulations\textsuperscript{24,28,29}. Prior to the transient simulations, steady state simulations were conducted to characterize the pumps’ performances, i.e., pre- and post- design modification, with the benchmark operating conditions – 5.3 L/min and 11.4 kPa of cardiac output and pressure head, accordingly that were provided by Abbott Labs. Moving reference frame was...
employed for modeling the spinning impeller – defined on the impeller segment cell zones with the designated angular velocities, with zero angular velocity applied on the shroud no-slip condition surfaces. Similarly, stationary cell zones were applied on the aft segments with designated angular velocities defined on the aft-impeller surfaces. 9.548 × 10⁻² kg/s and 0 Pa of mass flow rate and pressure were applied as the inlet and outlet boundary conditions correspondingly for each device, and series of steady state simulations were conducted by adjusting the impeller speed until the designated pressure head of 11.4 × 10³ Pa was reached – 10,600 and 11,600 rpm for the MINDTE and the MAXDTE, correspondingly (Fig. 2B). Two-way coupled discrete phase model (DPM) was employed during the transient simulations. Approx. 9.8 × 10³ buoyant 3 μm diameter spherical particles (998.2 kg/m³ of density) representing platelets were seeded and released from the upstream of both designs as flow tracers, corresponding to physiological concentration of a single cross-sectional batch of platelets traveling through the VADs. An optimized time step size of 7.53 × 10⁻⁵ s was utilized, and a simulation duration of 0.105 s was determined for both VADs to ensure at least 90% of the platelet population had exited the flow domains. The MINDTE and MAXDTE reached 18.55 and 20.3 rotations, respectively, during the simulations.

The platelet trajectories and their instantaneous stress tensor components were recorded at each time step, and extracted subsequent to each simulation. The stress tensor of each particle was then rendered into a scalar stress value (\(\sigma\)).

\[
\sigma = \sqrt{\frac{\tau_{11}^2 + \tau_{22}^2 + \tau_{33}^2 - \tau_{11}\tau_{22} - \tau_{11}\tau_{33} - \tau_{22}\tau_{33} + 3(\tau_{13}^2 + \tau_{23}^2 + \tau_{13}^2)}{3}}
\]

(1)

The cumulative stresses that may drive platelets beyond their activation threshold were calculated along multiple flow trajectories as follows: the stress loading history in each platelet trajectory is calculated by summing the instantaneous linear product of the scalar stress value and the exposure time (\(t_{exp}\)) – termed Stress Accumulation (SA) according to:

\[
SA = \sigma \cdot t_{exp} = \int_{t_0}^{t_{exp}} \sigma(t)dt = \sum_{i=1}^{N} \sigma_i \cdot \Delta t
\]

(2)

where \(\sigma_i, i = 1, 2, \ldots, N\), is the nodal scalar value extracted from the total stress tensor and \(\Delta t\) is the corresponding time step between successive nodal points.
To statistically represent the distribution of the large ensemble of stress accumulation (SA) values—each reached by a platelet along its flow trajectory, the statistical distribution of this large SA ensemble is collapsed into a probability density function (PDFs) curve—representing the device ‘thrombogenic footprint’\(^\text{22-24}\) that allows for expedient comparison of the thrombogenic potential generated in the varying designs. To compare the statistical distribution of stress accumulations of different platelet populations, while guaranteeing that the percentage activation is independent of variations in the number of seeded particles and spatiotemporal variations, we have interpolated between the smaller and larger populations’ statistical distributions by applying bootstrapping statistics\(^\text{23}\) to guarantee that PDFs from the different population sizes are compatible and comparable.

Regions of interest (ROI) analyses were conducted based on the cell zone segments – stator, bearing, impeller-shroud gap, blade, and lower-impeller— to evaluate the local thrombogenic potentials affected by specific design modification in these regions (Fig. 3).

**In vitro experiments.** Abbott Labs provided two VAD\(_{\text{proto}}\) pumps for testing purposes: MIN\(_{\text{DTE}}\) and the MAX\(_{\text{DTE}}\) were prototyped by Abbott for conducting the *in vitro* and *in vivo* experiments. The operating conditions obtained through steady state simulations (i.e., 10,600 and 11,600 rpm for the MIN\(_{\text{DTE}}\) and MAX\(_{\text{DTE}}\) pump speeds, respectively, and 5.3 L/min of cardiac output) were applied for calibrating the *in vitro* recirculation flow-loop which consisted of segments of \(\frac{\text{3/8}}{\text{"}}\) and \(\frac{\text{1/4}}{\text{"}}\) inner diameter (ID) Tygon R3603 tubes. The length of the \(\frac{\text{3/8}}{\text{"}}\) ID tubes controlled the pressure head across the VAD\(_{\text{x22,24}}\), and series of reducing connectors, i.e., \(\frac{\text{1/2}}{\text{"}} - \frac{\text{3/8}}{\text{"}}\) and \(\frac{\text{3/8}}{\text{"}} - \frac{\text{1/4}}{\text{"}}\) (NovoSci, Conroe, TX), were employed to avoid a sudden expansion and reduction of flow with the transition to the flow resistor\(^\text{24}\).

Citrated blood (120 ml) was obtained from consented healthy adult volunteers (\(n = 13\)) who had abstained from antithrombotic medications, e.g., aspirin and ibuprofen, for at least two weeks prior to blood donation. The fresh blood was collected through venipuncture according to a protocol approved by Stony Brook University IRB. Gel-filtered platelets were prepared and diluted to a concentration of \(15 \times 10^3 / \mu\text{l}\) with modified Tyrode’s buffer\(^\text{22,24}\). For the thrombogenicity measurements the platelet-buffer solution was recirculated in the flow-loop for 30 min with 10 min sampling intervals (\(t = 0, 10, 20 \text{ and } 30 \text{ min}\) utilizing the established platelet activity state (PAS) assay that reports thrombin generation rates\(^\text{22,24}\). PAS assay employs acetylated prothrombin to inactivate the positive feedbacks during shear-induced platelet activation to reach an one-to-one correlation between the shear dosage and the thrombin generation\(^\text{33}\). The linearly fitted slopes of the time sampled PAS values (normalized by thrombin generation rates achieved by platelets that are fully activated by sonication) represent the platelet activation rate (PAR) during the 30 min recirculation experiments. Experiments for both devices were conducted simultaneously using the same platelet batches to limit the study variability.

**Statistical analysis in silico.** The SA from the platelet trajectories was collapsed into the probability density function (PDFs) curve, which concept is an integral part of the numerical methods, and is explained above accordingly. *In vitro* – The PAR for each device was obtained by taking the linear fitting slope of the averaged time sampled PAS values. A secondary individual-experiment-based PAR calculation was achieved by averaging the linear fitting slope from individual experiments. Student’s \(t\)-test was utilized to conduct the statistical comparison of the *in vitro* results between the MIN\(_{\text{DTE}}\) and MAX\(_{\text{DTE}}\) with a significance level \(\alpha = 0.05\). A presumed sample size of 10, based on our previous studies, was employed before conducting sample size calculation to reach the 95% confidence level. Results are presented as the mean \(\pm\) standard error of the mean (SEM), unless otherwise stated\(^\text{22,24}\).

**In vivo animal experiments.** The bovine calf model has been extensively utilized to evaluate mechanical circulatory support devices\(^\text{34-37}\). Chronic animal studies (30 days) were conducted with the two experimental VAD prototypes implanted in young healthy adult calves (approx. 100 kg to congruent to human size) according
to an IACUC protocol approved by University of Arizona (the implantation site) and Stony Brook University. The animals received humane care in compliance with the “Principles of Laboratory Animal Care” (NIH Publication No. 85–23, revised 1985). Briefly, following general anesthesia, VADs were implanted via standard left intercostal thoracotomy, the inflow cannula of the pumps were inserted into the left ventricle (LV) and secured, with outflow grafts anastomosed to the ascending aorta. Pumps were initially run at a lower speed of 7500 rpm. After verifying device functional safety, pump speed was increased to the corresponding operating rpm of each VAD prototype. Upon closing the chest, a single driveline for both operation and/or powering of the LVAD was exteriorized. Post-operatively calves were transferred from the OR and placed in sternal recumbency in an ICU stanchion cart and were monitored continuously by veterinary staff until stable, up to 7 days post-op. The veterinary staff determined when a calf could return to standard housing. The VAD implanted was battery powered by an external controller, allowing the calf to be free from the stanchion when necessary.

Routine platelet activity state measurements were conducted on blood samples extracted from the animals using the PAS assay. Blood samples from the animals were collected in 10% ACD-A at pre-implant (before prepping for surgery), and post-operative day (POD) 0, 1, 2, 3, 4, 5, 7, 9, 14, 18, 21, 25, 28, and 30 (termination). Platelet rich plasma (PRP) was collected for the PAS assay. Chemistry panel (CP), Complete Blood Count (CBC), Basic Metabolic Panel (BMP), and Coagulation Panel were examined daily for clinical assessment. Additionally, thromboelastogram (TEG) was used to measure coagulation. The animals were kept with continuous IV heparin infusion, while bridging to warfarin (BID), maintaining ACT >220s and INR of 1.8–2.8, respectively. 2D and M-mode echocardiography was used to analyze VAD function and cardiac flow. Euthanasia was performed according to the approved protocol at the completion of the experiment or if termination was needed for other clinical reasons. Calves were heavily sedated with Ketamine 3–4 mg/kg IV to ensure recumbency, and were given an IV barbiturate overdose (Beuthanasia-D) 1cc/10lbs IV . Post euthanasia, gross examination of devices was performed, including examination of the implant site and of device zones (intra-device, via internal examination and device sectioning). In addition, histologic evaluation of the device-tissue interface, device zones (intra-device) and detailed scanning electron microscopy of critical device internal zones and subcomponents was also performed.

Use of human participants. Consent was obtained for all the fresh blood donations obtained from healthy adult volunteers according to Stony Brook University Committee on Research Involving Human Subjects approved protocol (CORIHS 2012-4427-R4). All experiments were performed in accordance with relevant guidelines and regulations.

Use of experimental animals. Chronic animal studies were conducted according to an IACUC protocol approved by the implantation site at the Sarver Heart Center, University of Arizona (UAZ IACUC Protocol#10–193), additionally approved by Stony Brook University (IACUC 2012-1992-FAR-USDA). The animals received humane care in compliance with the “Principles of Laboratory Animal Care” (NIH Publication No. 85–23, revised 1985). All experiments were performed in accordance with relevant guidelines and regulations.

Results

*In silico simulations.* The flow is depicted by two perpendicular cross-sections showing the velocity vectors flow field within MINDTE. Distinct regions of high velocities are formed at the gap clearance between the top of the impeller blade and the shroud (in red) and recirculation zones are formed towards the outflow tract where the blood flow is converted from axial to centrifugal (Fig. 4). The flow trajectories of a cluster of 9.8 × 10^3 platelets that were released upstream (as described) was then tracked along the flow through the VAD, and used to compute for each individual platelet flow trajectory the resultant stress accumulation (SA) value that may drive the platelet beyond its activation threshold. Several highest SA generating platelet trajectories of platelets flowing through the MINDTE impeller region are shown in Fig. 5, indicating entrapped trajectory patterns along the impeller. The large SA ensemble was then collapsed into a probability density function (PDFs) curve, as explained in Methods. The global PDFs of MINDTE and MAXDTE (Fig. 6) indicated that: (i) the main mode of MINDTE SA distribution populated the lower SA range as compared to that of the MAXDTE main mode; (ii) the MAXDTE main mode had a wider SA distribution (2–30 dyne·s/cm²) as compared to that of the MINDTE main mode (3–15 dyne·s/cm²); (iii) comparing the SA distribution at the tail regions of the PDFs that are riskier, i.e., prone to activate platelets (SA >50 dyne·s/cm²), a secondary and tertiary modes were found for the MAXDTE, indicating that platelets flowing through the MAXDTE have significantly higher probability to be exposed to higher SA levels than the MINDTE. The secondary and tertiary modes of the MAXDTE populated the highest SA range (SA >150 dyne·s/cm²) and extended further – as compared to that of the MINDTE secondary mode (SA range of 130–160 dyne·s/cm²) (Fig. 6).

A closer look at the ROI comparative PDF results at the stator region (Fig. 7) indicates that the PDF main mode of MAXDTE was shifted towards the higher SA range (to the right), with more spread out and higher probability for larger SA values distribution as compared to the MINDTE. At the bearings region, the MAXDTE main mode was similarly shifted towards the higher SA range, with similar SA distribution. At the impeller–shroud gap region, the MAXDTE had a main bimodal distribution, and the higher larger distribution in the 4–20 dyne·s/cm² SA range; however, it had a shorter higher SA range tail. Distinct differences were found at the impeller blade region, not only in the main mode of the MAXDTE, that populated the higher SA range and a far longer tail region distribution. For the lower impeller region, the MAXDTE shared similar distribution distributions as the original MINDTE; however, the entire distribution was offset toward the higher SA range (as shown in Fig. 7).

*In vitro platelet activity state (PAS) measurements.* The *in vitro* measurements of the platelet activity over 30 min. recirculation time through both VADs indicated that the thrombogenicity level of the MAXDTE (expressed as the platelet activity rate (PAR) — the slope of the PAS measurements over this circulation time)
**Figure 4.** Two perpendicular cross-sections of the instantaneous velocity flow field within the MIN\textsubscript{DTE} from a single freeze frame. High flow velocities were observed at the gap clearance between the impeller and the shroud. In addition, recirculation zones formed towards the outflow tract where the flow is converted from axial to centrifugal (inset).

**Figure 5.** Typical platelet flow trajectories around the rotating impeller are shown (inset)—used to compute the Stress Accumulation (SA). The top ten highest SA generating platelet trajectories in the MIN\textsubscript{DTE} impeller regions.

**Figure 6.** Global PDF results between the MIN\textsubscript{DTE} (blue) and the MAX\textsubscript{DTE} (red) VADs. The main mode of the MAX\textsubscript{DTE} appeared to have wider distribution and located at the higher SA range, compared with the MIN\textsubscript{DTE} main mode. Higher platelet distribution was also found in the tail region (i.e., SA > 50 dyne·s/cm²) of the MAX\textsubscript{DTE}, which represented more platelets traverse through would experience higher levels of shear stress (inset).
was approx. 5-fold higher than that of the MIN

DTE (Fig. 8; PAR = 4 × 10⁻⁴ m⁻¹ and 8 × 10⁻⁵ m⁻¹ for the MAX

DTE and the MIN

DTE, respectively, n = 13, p ≤ 0.03). A comparative PAR calculation based on individual experiments reveals a 3-fold differences between the MAX

DTE and MIN

DTE (Fig. 8, inset). This corroborated the in silico simulation results where the PDFs (the ‘thrombogenic footprint’) clearly showed a much higher probability of platelets being exposed to elevated SA in the case of the MAX

DTE strongly correlating to the measured higher platelet activation rate.

Chronic in vivo animal experiments. Distinct differences were observed between the animals that were implanted with the MIN

DTE and the MAX

DTE in the chronic animal studies. By onset of post-implantation day
2 the platelet activity state measurements indicated that both animals experienced an acute platelet activation peak, with similar trends of platelet count found in the two animals (Fig. 9, top). The calf implanted with the MIN\textsubscript{DTE} recuperated and survived well throughout the 30 days experiment. However, the calf implanted with the MAX\textsubscript{DTE} did poorly, resulting in early termination (POD 2) due to a sudden seizure with accompanying incapacitating stroke from thromboembolism, following which the animal was euthanized for humane reasons (Fig. 9, right-top).

Specifically, the platelet activity state (PAS) of the calf implanted with the MIN\textsubscript{DTE} peaked by POD1, likely due to the insult of surgery and peri-operative inflammation, but subsequently declined by POD4 (Fig. 9, left-top; black) with early healing. By POD5 PAS samples indicated a general trend up for the rest of the study. The activity state of platelets appeared to correlate with the white blood count and lactate dehydrogenase (LDH) levels (not shown) but not with the platelet count (Fig. 9, left-top; purple) or fibrinogen level. At the end of the 30 days chronic study, post-mortem gross and microscopic analysis revealed signs of tissue deposition on the inflow cannula and ingrowth lamination of cells on the outflow graft. There were no sign of thrombosis at the anastomosis region or the outflow graft. Enhanced fibrin deposition (hypercoagulability) was observed on the inner ostium of the inflow cannula, as well as in the disassembled VAD components — within the pump (inlet stator and inlet bearing), and on the outflow graft lining. Thrombus accumulation around the inlet bearing was examined histologically and found to consist of a homogenized, acellular eosinophilic (proteinaceous) matrix material (denatured protein) that is hypothesized to have formed as a result of heat and/or rotational force). Phosphotungstic acid-haematoxylin (PTAH) staining for fibrin confirmed the presence of condensed fibrin laminates within the thrombus material. Distinct contained regions of white thrombus were found at the inlet bearing (ball) of the impeller (Fig. 9, left-bottom).

The post mortem examination of the MAX\textsubscript{DTE} explanted from the animal revealed evident thrombus in the LV adjacent to the inflow cannula and within the inflow port from the left ventricle that was 40% occluded by a red thrombus (Fig. 9, right-bottom). The outflow graft revealed thrombus in the peri-outflow region. Examination of the disassembled VAD components revealed a large red thrombus with evident adherent thrombus at the front bearing (ball) that was widely distributed from there all along the impeller, as well as around the aft region of the MAX\textsubscript{DTE} impeller, likely resulting from the presence of recirculation and stagnation flow caused by the design modification (Fig. 9, right-bottom). Whitish older thrombus across the rotor was more adherent and extended from just distal to the bearing across the notch down to the aft portion of the impeller. MRI of the brain of the animal revealed large evident thromboemboli in major vessels surrounding the brain with clear evidence of parenchymal infarction.

**Discussion**

The MAX\textsubscript{DTE}, with the partial impeller blades (5 mm gap) was expected to have a significantly higher thrombogenic potential as compared to the MIN\textsubscript{DTE} design. The extensive *in silico* numerical simulations and analysis of the thrombogenic potential (via the statistical PDF distribution of the stress accumulation along a large ensembles of individual platelet flow trajectories though each device, that provides the ‘thrombogenic footprint’ of the design), clearly showed the marked differences between the two VAD designs. This was confirmed by comparing both the global PDFs of the devices, as well as by a closer examination and comparison in specific regions of

| MIN\textsubscript{DTE}          | MAX\textsubscript{DTE}          |
|-------------------------------|-------------------------------|
| **Platelet Activation States** |                               |
| Normalized PAS                |                               |
|                               |                               |
| **Platelet Count & Platelet** |                               |
|                               |                               |
|                               |                               |

**Figure 9.** Chronic *in vivo* animal experimental results for the MIN\textsubscript{DTE} (left column) and the MAX\textsubscript{DTE} (right column). The top row shows the platelet activation state and platelet counts for each implanted device. The bottom row shows the post-mortem explanted devices. White thrombus was observed at the entry of the impeller in MIN\textsubscript{DTE}, and red thrombus was observed widely distributed along the MAX\textsubscript{DTE} impeller and its aft.
interest (ROI). Physical prototype devices representing MIN\textsubscript{DTE} and MAX\textsubscript{DTE} were provided and tested in recirculation flow loops under typical VAD operating conditions, wherein the platelet activity generated by each was measured and compared. The in vitro results confirmed the numerical simulations that predicted a much higher thrombogenic potential for the MAX\textsubscript{DTE}. The platelet activity measurements performed in vitro in the actual pump prototypes operating under clinical conditions in circulation flow loops generated approx. 5-fold significantly higher thrombogenicity (in terms of platelet activity) as compared to the MIN\textsubscript{DTE}. This in vitro validation of the DTE methodology was further corroborated by the subsequent in vivo chronic animal studies. The animal implanted with the MIN\textsubscript{DTE} prototype survived well and thrived throughout the 30 day experiments. While it was expected that the animal implanted with the MAX\textsubscript{DTE} would fare inferiorly, the much higher thrombogenicity levels generated by the device led to catastrophic thromboembolic complications, leading to stroke, seizure and incapacity, with early termination of the study. The post-mortem analyses of the, e.g., MIN\textsubscript{DTE} showed that white thrombus were formed at the impeller front bearing region (Fig. 9, left- bottom). This pattern closely matched the location where entrapped high SA platelet trajectories were found in the MIN\textsubscript{DTE} simulations (Fig. 5), and is very similar to the thrombus formation patterns observed in explanted HMII VADs\textsuperscript{9,10,35,40}. The red thrombus found throughout the explanted MAX\textsubscript{DTE} impeller (Fig. 9, right- bottom) matched the presence of stagnation and recirculation zones caused by the intentional design modification, which additionally led to reduction of the pump efficiency. The depositions of white and red thrombus in MIN\textsubscript{DTE} and MAX\textsubscript{DTE}, respectively, reveals the distinct flow environments of the two devices. Platelets entrapped at the entry of MIN\textsubscript{DTE} impeller exposed to high shear dosage while spinning along with the higher RPM impeller, thus the high shear related white thrombus was formed\textsuperscript{7}. The red thrombus deposited along the MAX\textsubscript{DTE} impeller revealed that the fluid flow field was majorly disturbed due to the partial removal of impeller blades. Pump efficacy reduced leads to the formation of recirculation zones and stagnation flow, which leads to low-flow associated thrombus, i.e., red thrombus\textsuperscript{7}.

Limitations
Isolated platelets were used in the present experiments to examine the direct effect of various device associated shear environments on thrombin generation without the subsequent feedback and platelet aggregation. The platelets were diluted to a concentration of 15,000 µL due to the limited available donor blood volume and the relatively large flow loop volume. These limitations may not directly represent the physiological response of whole blood, which consists of other blood cells and plasma proteins, via which the platelet shear-induced activation is amplified. Although flow cytometry is capable of providing detailed information regarding platelet membrane glycoprotein activity, and has been utilized in several VAD studies\textsuperscript{41,42}, here the PAS assay was utilized due to its ability to provide near-real time information on shear-induced bulk platelet thrombin generation. The DTE predictive capability would have been established more rigorously if a larger study, involving more animals, was conducted. However, such a study would necessitate near insurmountable cost and complexity. Furthermore, the present DTE experiments well demonstrate and underscore the predictive capacity of DTE. While it is recognized that DTE is far removed from the “wet” physiological scenario, such a reductionist approach is capable of predicting outcomes directly from in silico to in vivo.

In silico simulations and in vitro experiments have been widely employed during the R and D phases of VAD development. Previous VAD studies have demonstrated the robust capability of using advanced CFD to examine the intra-device flow conditions and shear environment\textsuperscript{13,44}, leading to predictions of hemolysis\textsuperscript{29,32} or platelet activation\textsuperscript{22,24}. In vitro experiments were mainly employed to evaluate intra-device flow environments in previous studies\textsuperscript{45}, with some groups beginning to utilize in vivo experiments for examining hemolysis caused by minor design modifications\textsuperscript{46}. However, in contrast, DTE is a pioneering concept in that it couples in silico simulations, in vitro studies and in vivo experiments together, developing a predictive methodology to anticipate in vivo trial outcomes numerically.

Conclusions
The DTE methodology demonstrates the use of advanced numerical simulations combined with experimental techniques for quantifying measures that are directly relevant to thrombosis and coagulation markers in devices, that is predictive of how devices may perform in vivo. The veracity of the DTE in silico simulations predictive capability was validated by in vitro recirculation experiments, and further translated and confirmed by in vivo VAD implantation animal studies. The robust capability of this predictive technology demonstrates its utility as a cost-effective pre-clinical MCS thrombo-optimization approach. DTE offers the potential to transform the conventional approach currently utilized for designing and developing MCS devices. Presently numerous, costly, burdensome in vivo animal studies are required during each development cycle. DTE-enhanced design offers the potential of a more direct approach, with a priori enhanced hemocompatibility (Fig. 1), ultimately reducing both the time and cost of device development. Further, this approach may eventually obviate the need for animal experiments, providing a useful adjunct to enhance regulatory science approaches and approval.

Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request. The data of design iterations that were performed during this study are available from Abbott Labs, but restrictions apply to the availability of these data which are not publicly available.

References
1. FDA. Thoratec HeartMate II LVAS - P060040/S005, http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm201473.htm (2010).
2. FDA. HeartWare Ventricular Assist System - P100047, http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm330838.htm (2012).
3. FDA. HeartMate 3 Left Ventricular Assist System (LVAS) - P160054/S008, https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm624155.htm (2018).

Scientific Reports | (2019) 9:2946 | https://doi.org/10.1038/s41598-019-39897-6
4. Slepian, M. J. et al. Shear-mediated platelet activation in the free flow: Perspectives on the emerging spectrum of cell mechanobiological mechanisms mediating cardiovascular implant thrombosis. J Biomech. 50, 20–25, https://doi.org/10.1016/j.jbiomech.2016.11.016 (2017).

5. Baumann Kreuziger, L. M. Management of anticoagulation and antiplatelet therapy in patients with left ventricular assist devices. J Thromb Thrombolysis 39, 357–344, https://doi.org/10.1007/s11239-014-1162-5 (2015).

6. Baumann Kreuziger, L. M., Kim, B. & Wiesbhalder, G. M. Antithrombotic therapy for left ventricular assist devices in adults: a systematic review. J Thromb Haemost 13, 946–955, https://doi.org/10.1111/jth.12948 (2015).

7. Blizu, A. Pump thrombosis—A riddle wrapped in a mystery inside an enigma. Ann Cardiothor Surg 3, 450–471, https://doi.org/10.3978/j.issn.2225-319X.2014.09.10 (2014).

8. Kirklin, J. K. et al. Pump thrombosis in the Thoratec HeartMate II device: An update analysis of the INTERMACS Registry. J Heart Lung Transplant 34, 1515–1526, https://doi.org/10.1016/j.healun.2015.10.024 (2015).

9. Meyer, A. L. et al. Thrombus formation in a HeartMate II left ventricular assist device. J Thorac Cardiovasc Surg 135, 203–204, https://doi.org/10.1016/j.jtcvs.2007.08.048 (2008).

10. Mokadam, N. A., Andrus, S. & Ungerleider, A. Thrombus formation in a HeartMate II. Eur J Cardiothor Surg 39, 414, https://doi.org/10.1016/j.ejcts.2010.06.015 (2011).

11. Najib, M. Q., Wong, R. K., Pierce, C. N., DeValeria, P. A. & Chaliki, H. P. An unusual presentation of left ventricular assist device thrombosis. Eur Heart J Cardiovasc Imaging 13, 532, https://doi.org/10.1093/ehjci/jet011 (2012).

12. Samson, R. et al. Device Thrombosis During Destination Therapy. Am J Med Sci 351, 441–446, https://doi.org/10.1016/j.amjms.2016.01.015 (2016).

13. Smedira, N. G. et al. Current risks of HeartMate II pump thrombosis: Non-parametric analysis of Interagency Registry for Mechanically Assisted Circulatory Support data. J Heart Lung Transplant 34, 1527–1534, https://doi.org/10.1016/j.healun.2015.10.027 (2015).

14. Starling, R. C. et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 370, 33–40, https://doi.org/10.1056/NEJMoai1313855 (2014).

15. Valerio, L. et al. Routine clinical anti-platelet agents have limited efficacy in modulating hypershear-mediated platelet activation associated with mechanical circulatory support. J Thromb Res 165, 162–171, https://doi.org/10.1016/j.thromres.2017.12.001 (2018).

16. Valerio, L. et al. Aspirin has limited ability to modulate shear stress induced hypertension in a mechanical heart valve: numerical study. Artif Organs 38, 477–488, https://doi.org/10.1111/1525-1594.12554 (2014).

17. Amer, S., Shah, P. & Hassan, S. Gastrointestinal bleeding with continuous-flow left ventricular assist devices. Clin Gastroenterol 8, 63–67, https://doi.org/10.1016/j.cga.2015.05.051 (2015).

18. Draper, R. V., Huang, R. J. & Gerson, L. B. GI bleeding in patients with continuous-flow left ventricular assist devices: a case report. PLoS One 9, e94643, https://doi.org/10.1371/journal.pone.0094643 (2014).

19. Eckman, P. M. & John, R. Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. Circulation 125, 3038–3047, https://doi.org/10.1161/CIRCULATIONAHA.111.040246 (2012).

20. Geisen, U. et al. Non-surgical bleeding in patients with ventricular assist device could be explained by acquired von Willebrand disease. Eur J Cardiothor Surg 33, 679–684, https://doi.org/10.1016/j.ejcts.2007.12.047 (2008).

21. Alemu, Y. & Bluestein, D. Flow-induced platelet activation and damage accumulation in a mechanical heart valve: numerical study. Artif Organs 31, 677–688, https://doi.org/10.1111/1525-1594.2007.00447.x (2007).

22. Girdhar, G. et al. Device thrombogenicity emulation: a novel method for optimizing mechanical circulatory support device thromboresistance. PLoS One 7, e32463, https://doi.org/10.1371/journal.pone.0032463 (2012).

23. Xenos, M. et al. Device Thrombogenicity Emulator (DTE)—design optimization methodology for cardiovascular devices: a study in two bileaflet MHV designs. J Biomech 43, 2400–2409, https://doi.org/10.1016/j.jbiomech.2010.04.020 (2010).

24. Chiu, W. C. et al. Thromboresistance comparison of the HeartMate II ventricular assist device with the device thrombogenicity emulation—optimized HeartAssist 5 VAD. J Biomech Eng 136, 021014, https://doi.org/10.1115/1.4026254 (2014).

25. Chiu, W. C., Slepian, M. J. & Bluestein, D. Thrombus formation patterns in the HeartMate II ventricular assist device: clinical observations can be predicted by numerical simulations. ASAIO J 60, 237–240, https://doi.org/10.1097/MAT.0000000000000034 (2014).

26. Sherif, I. et al. Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device. J Thromb Thrombolysis 37, 499–506, https://doi.org/10.1007/s11239-013-0997-6 (2014).

27. ANSYS. ANSYS Fluent Theory Guide (2015).

28. Chiu, W. C. et al. Ventricular Assist Device Implantation Configurations Impact Overall Mechanical Circulatory Support System Thromboresistance Potential. ASAIO J 63, 285–292, https://doi.org/10.1097/MAZ.0000000000000088 (2017).

29. Fraser, K. H., Zhang, T., Taskin, M. E., Griffin, B. P. & Wu, Z. J. A quantitative comparison of mechanical blood damage parameters in rotary ventricular assist devices: shear stress, exposure time and hemolysis index. J Biomech Eng 134, 018002, https://doi.org/10.1115/1.4007902 (2012).

30. Marom, G. & Bluestein, D. Lagrangian methods for blood damage estimation in cardiovascular devices—How numerical implementation affects the results. Expert Rev Med Devices 13, 113–122, https://doi.org/10.1586/17434440.2016.1133283 (2016).

31. Bluestein, D., Ramboz, E. & Garhir, M. Vortex shedding as a mechanism for free emboli formation in mechanical heart valves. J Biomech Eng 122, 125–134 (2000).

32. Apel, J., Paul, R., Klaus, S., Siess, T. & Reul, H. Assessment of hemolysis related quantities in a microaxial blood pump by computational fluid dynamics. Artif Organs 25, 341–347 (2001).

33. Jesty, J., Yin, W., Perrotta, P. & Bluestein, D. Platelet activation in a circulating flow loop: Combined effects of shear stress and exposure time. Platelets 14, 143–149, https://doi.org/10.1080/0953710300010009239 (2003).

34. Yin, W. et al. Thrombogenic performance of a st. Jude bileaflet mechanical heart valve in a sheep model. ASAIO J 52, 28–33, https://doi.org/10.1097/01.mat.0000198123.42686.ca (2006).

35. Capoccia, M., Bowles, C. T., Sabashnikov, A. & Simon, A. Recurrent Early Thrombus Formation in HeartMate II Left Ventricular Assist Device. J Invest Med High Impact Case Rep 1, 2324709613490676, https://doi.org/10.1177/2324709613490676 (2013).

36. Slaughter, M. S. et al. Platelet activation in heart failure patients supported by the HeartMate II ventricular assist device. Int J Artif Organs 34, 461–468, https://doi.org/10.5301/IJO.2011.8459 (2011).

37. Houel, R. et al. Platelet activation and aggregation profile in prolonged external ventricular support. J Thorac Cardiovasc Surg 128, 197–202, https://doi.org/10.1016/j.jtcvs.2003.11.059 (2004).
43. Zhang, J., Zhang, P., Fraser, K. H., Griffith, B. P. & Wu, Z. J. Comparison and experimental validation of fluid dynamic numerical models for a clinical ventricular assist device. Artif Organs 37, 380–389, https://doi.org/10.1111/aor.12525-1594.2012.01576.x (2013).
44. Medvitz, R. B., Reddy, V., Deutsch, S., Manning, K. B. & Paterson, E. G. Validation of a CFD methodology for positive displacement LVAD analysis using PIV data. J Biomech Eng 131, 111009, https://doi.org/10.1115/1.4000116 (2009).
45. Tree, M. et al. In Vitro Examination of the HeartWare CircuLite Ventricular Assist Device in the Fontan Connection. ASAIO J 63, 482–489, https://doi.org/10.1097/MAT.0000000000000521 (2017).
46. Li, D. et al. Lactic Dehydrogenase in the In Vitro Evaluation of Hemolytic Properties of Ventricular Assist Device. Artif Organs 41, E274–E284, https://doi.org/10.1111/aor.12943 (2017).

Acknowledgements
This project was supported by grants from the National Institute of Biomedical Imaging and Bioengineering: Quantum Award Phase I R01, EB008004 (DB) and Quantum Award: Implementation Phase II- 1U01EB012487 (DB).

Author Contributions
Wei Che Chiu performed the numerical simulations, the in vitro experiments and their analysis, and wrote the initial draft. Phat L. Tran, and Zain Khalpey performed the in vivo experiments and analyzed their results. Eric Lee and Yi-Ren Woo performed design iterations and manufactured the VAD prototypes. Marvin J. Slepian coordinated, participated in and oversaw the in vivo experiments, interpreted their results, and helped in writing the manuscript. Danny Bluestein oversaw and coordinated all aspects of the project, led and participated in all aspects of the numerical simulations and the in vitro experiments, and wrote the manuscript.

Additional Information
Competing Interests: Authors Eric Lee and Yi-Ren Woo were senior research engineers employed by Thoratec Corporation at the time of this research project (since acquired by Abbott Labs). Authors Wei Che Chiu, Phat L. Tran, Zain Khalpey, Marvin J. Slepian and Danny Bluestein have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2019